Clinical trial
A Phase Ib Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Dose Escalation, Safety and Tolerability Study of PRTX-100 in Combination With Methotrexate or Leflunomide in Patients With Active Rheumatoid Arthritis
NCT01749787 is registered in ClinicalTrials.gov with Protalex, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase Ib Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Dose Escalation, Safety and Tolerability Study of PRTX-100 in Combination With Methotrexate or Leflunomide in Patients With Active Rheumatoid Arthritis
- Lead sponsor
- Protalex, Inc.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- November 30, 2012
- Completion date
- August 31, 2014
- Enrollment
- 61 (actual)
- Sites
- 8
Conditions
As the registry lists them; a condition with its own page is linked.